Upon reflection I see a more positive spin on today's PR. Apparently SR had requested a 30 patient open trial in addition to that of 60 (30+30) Randomized, Double-Blind, and Placebo-Controlled with intention to compare the dosages. In one of recent CCs he mentioned that more is not always better. In a way it's like one trial 30 (350 mg)+30 (700 mg) +30 (placebo) with two dosages against the same number of placebo patients. So it makes sense to begin with top results for 350 mg vs placebo since the open trial data were already known while the 700 mg cohort data would take longer time to assemble, especially considering the holidays, Omicron and 4 different trial sites.